---

COCHLEAR OTOSCLEROSIS

A Comprehensive Answer for 50 Marks | RGUHS MS ENT Standard

---

INTRODUCTION

"Extension of otosclerosis beyond the stapes footplate to involve the cochlea (cochlear otosclerosis) can lead to mixed or sensorineural hearing loss." — Harrison's Principles of Internal Medicine, 21st Ed. (p. 1024)

---

HISTORICAL BACKGROUND

---

ANATOMY OF THE OTIC CAPSULE

┌─────────────────────────────────────────────────────┐
│              LAYERS OF OTIC CAPSULE                  │
│                                                      │
│  1. PERIOSTEAL LAYER (outer)                         │
│     ↓                                                │
│  2. ENCHONDRAL LAYER (middle) ← PRIMARY SITE OF      │
│     [Globuli ossei / intrachondral islands]           │
│     OTOSCLEROTIC FOCI                                │
│  3. ENDOSTEAL LAYER (inner)                          │
└─────────────────────────────────────────────────────┘

---

SITES OF PREDILECTION

COMMON SITES OF OTOSCLEROTIC FOCI (in order of frequency):

1. FISSULA ANTE FENESTRAM ──────────── 80–90% (Fenestral type)
   (anterior to oval window)

2. ROUND WINDOW NICHE ──────────────── 30%
   (may cause round window obliteration)

3. PERICOCHLEAR / ENDOCOCHLEAR ─────── Cochlear type
   ├─ Surrounding scala vestibuli
   ├─ Surrounding basal turn of cochlea
   └─ Internal auditory canal (rare)

4. INTERNAL AUDITORY CANAL ──────────── Rare

Cochlear (Retrofenestral) otosclerosis specifically involves pericochlear spread — surrounding the scala vestibuli, basal turn, and whole cochlear capsule. (Scott-Brown's Otorhinolaryngology, 8th Ed.)

---

EPIDEMIOLOGY

---

ETIOLOGY AND PREDISPOSING FACTORS

1. Genetic Factors (Primary)

• Autosomal dominant inheritance with 25–40% penetrance (Harrison's, p. 1024)
• Multiple loci identified: OTSC1 (15q25-26), OTSC2 (7q34-36), OTSC3 (6p21.3-22.3), OTSC4, OTSC5, OTSC7, OTSC8
• COL1A1 gene mutation (type I collagen) — associated with osteogenesis imperfecta overlap
• TGFB1 (Transforming Growth Factor Beta-1) — promotes osteoblast activity

2. Viral Hypothesis

• Measles virus (paramyxovirus RNA) has been detected in otosclerotic foci
• Anti-measles antibody titers elevated in perilymph of otosclerosis patients
• The measles vaccination program may be contributing to declining incidence (Hazarika, Textbook of ENT & HNS)

3. Hormonal Factors

• Estrogen accelerates the otosclerotic process
• Disease worsens/presents during pregnancy and with OCP use
• (Harrison's, p. 1024: "In women, the otosclerotic process is accelerated during pregnancy")

4. Fluoride Deficiency

• Low fluoride in drinking water correlated with higher prevalence
• Sodium fluoride stabilizes bone by converting hydroxyapatite to fluorapatite (more stable)

5. Autoimmune / Inflammatory

• Elevated IL-1, TNF-α, and prostaglandins in otosclerotic foci
• Type II collagen autoantibodies implicated
• (Stell & Maran's Textbook of Head & Neck Surgery)

6. Vascular / Metabolic

• Otospongiosis — the active vascular phase; histologically shows dilated vascular channels (blue mantles of Manasse)

---

PATHOPHYSIOLOGY

Normal Otic Capsule vs. Otosclerosis

NORMAL OTIC CAPSULE:
Enchondral bone → STABLE (no Haversian remodeling)
Inhibited by: TGF-β, osteoprotegerin

OTOSCLEROSIS (DISORDERED REMODELING):
                  ┌──────────────────────┐
                  │  TRIGGERING FACTORS  │
                  │ (Virus/Hormones/Gene) │
                  └──────────┬───────────┘
                             ↓
              Activation of OSTEOCLASTS
                  (Abnormal bone resorption)
                             ↓
              Active Spongiotic Phase
           (Vascular, cellular — OTOSPONGIOSIS)
           [Blue mantles of Manasse histologically]
                             ↓
              Osteoblast Activation
                  (Irregular new bone deposition)
                             ↓
              Sclerotic / Mature Phase
           (Dense, sclerotic — OTOSCLEROSIS)
                             ↓
         ┌─────────────┴──────────────┐
         ↓                            ↓
  FENESTRAL LESION            COCHLEAR LESION
  (Stapes fixation)    (Pericochlear / Endocochlear)
  → Conductive HL             → SNHL / Mixed HL

Mechanism of SNHL in Cochlear Otosclerosis

Cochlear Otosclerosis
         │
         ├──→ 1. DIRECT ENZYMATIC TOXICITY
         │       Proteolytic enzymes & cytokines from
         │       active foci → diffuse into perilymph
         │       → damage hair cells (esp. basal turn)
         │
         ├──→ 2. MECHANICAL COMPRESSION
         │       Otosclerotic bone compresses spiral
         │       ligament, stria vascularis, cochlear
         │       nerve in IAC
         │
         ├──→ 3. VASCULAR COMPROMISE
         │       Obliteration of cochlear arterioles
         │       → ischemic hair cell damage
         │
         ├──→ 4. ROUND WINDOW OBLITERATION
         │       Blocks hydraulic compensation
         │       → increased endolymphatic pressure
         │
         └──→ 5. ENDOLYMPHATIC HYDROPS
                 Secondary hydrops from
                 altered fluid dynamics
                 → Meniere-like SNHL

---

HISTOPATHOLOGY

Stages of Otosclerotic Foci

Key Histological Features:

• Globuli ossei — precursor remnant cartilage islands
• Blue mantles of Manasse — basophilic halo around vascular channels in active phase (pathognomonic)
• Woven bone replacing the enchondral layer
• In cochlear involvement: endosteal new bone lining the scala tympani and vestibuli
• Atrophy of stria vascularis and degeneration of organ of Corti in advanced cases

---

CLASSIFICATION OF OTOSCLEROSIS

Gristwood & Venables Classification (Clinical):

Valvassori CT Classification (Radiological):

Rotteveel Grading System (HRCT — used in CI candidates):

---

CLINICAL FEATURES

Symptoms

• Insidious, progressive bilateral sensorineural or mixed hearing loss
• High-frequency SNHL predominates (basal turn of cochlea most affected)
• Unlike fenestral otosclerosis (low-frequency CHL), cochlear otosclerosis presents with high-frequency SNHL
• Can progress to profound/total deafness

• Present in 75% of cases
• Usually low-frequency hum in fenestral type; high-pitched in cochlear type
• One of the most distressing symptoms

• Paradoxical improvement of hearing in noisy environments
• Characteristic of fenestral type with conductive component
• May be absent in pure cochlear otosclerosis

• Occurs in ~25% — especially with cochlear involvement
• May manifest as secondary endolymphatic hydrops (Meniere-like syndrome)

• Only if fenestral + cochlear (mixed type)

Signs

---

AUDIOLOGICAL EVALUATION

Pure Tone Audiogram (PTA)

FENESTRAL OTOSCLEROSIS:
Frequency (Hz)  250  500  1000  2000  4000
Air Conduction:  40   45    50    55    60  dB ↓
Bone Conduction: 25   30    30    20    25  dB ↓
                          ↑
               CARHART'S NOTCH (mechanical artifact)
               Notch at 2000 Hz in bone conduction

COCHLEAR / RETROFENESTRAL OTOSCLEROSIS:
Air Conduction:  30   40    60    70    80  dB ↓
Bone Conduction: 30   40    60    70    80  dB ↓
Air-Bone Gap: ABSENT or MINIMAL
→ Pattern: SNHL (downsloping, high-frequency loss)

Tympanometry (Immittance Audiometry)

Speech Audiometry

• Speech Reception Threshold (SRT) elevated proportional to PTA
• Speech Discrimination Score (SDS/WRS) — reduced in cochlear involvement (below 70%)
• Poor SDS despite amplification suggests cochlear damage beyond conductive loss

Otoacoustic Emissions (OAEs)

• Absent DPOAEs and TEOAEs in cochlear otosclerosis (outer hair cell damage)
• Useful in distinguishing cochlear from purely conductive type

Auditory Brainstem Response (ABR)

• Increased absolute and interpeak latencies (Wave I–V)
• Used to assess retrocochlear function and cochlear reserve
• Critical before cochlear implant candidacy evaluation

---

RADIOLOGICAL EVALUATION

High-Resolution CT (HRCT) Temporal Bone

A pericochlear halo of hypodensity surrounding the cochlea — representing active demineralization of the otic capsule. This is the pathognomonic CT finding of cochlear (retrofenestral) otosclerosis.

HRCT TEMPORAL BONE — FINDINGS:

ACTIVE PHASE (Spongiotic):
├─ Hypodense halo around cochlea (Double ring sign)
├─ Reduced density of cochlear capsule
├─ Pericochlear lucency — basal turn > apical
└─ Involvement of round window niche

INACTIVE PHASE (Sclerotic):
├─ Sclerotic, thickened cochlear capsule
├─ Obliteration of round window
├─ Normal to increased density
└─ May simulate "dense" otic capsule

ASSOCIATED FINDINGS:
├─ Oval window narrowing (fenestral component)
├─ IAC narrowing (rare)
└─ Bilateral symmetric involvement (70%)

MRI (Limited role)

• Gadolinium-enhanced MRI: Shows enhancement of active otosclerotic foci (high vascularity)
• Used to exclude retrocochlear causes of SNHL
• Pre-CI assessment: cochlear patency, nerve integrity
• (Scott-Brown's 8th Ed.)

---

FLOWCHART: DIAGNOSTIC ALGORITHM FOR COCHLEAR OTOSCLEROSIS

PATIENT WITH PROGRESSIVE SENSORINEURAL / MIXED HEARING LOSS
                           │
                           ▼
              HISTORY & CLINICAL EXAMINATION
          ┌────────────────────────────────────┐
          │  • Age 20–50 yrs, F>M              │
          │  • Family history (AD)              │
          │  • Worsening in pregnancy           │
          │  • Bilateral (asymmetric onset)     │
          │  • No ear discharge, normal TM      │
          │  • Schwartze sign (if active)       │
          └───────────────┬────────────────────┘
                          ▼
                    AUDIOLOGICAL WORKUP
             ┌─────────────────────────────┐
             │ PTA: SNHL / Mixed HL        │
             │ Tympanogram: Type A or As   │
             │ Absent stapedial reflexes   │
             │ Absent OAEs                 │
             │ Carhart notch (if mixed)    │
             └──────────────┬──────────────┘
                            ▼
                  HRCT TEMPORAL BONE
         ┌──────────────────────────────────────┐
         │  Double ring sign (4th ring of        │
         │  Valvassori) = Pericochlear halo      │
         │  → CONFIRMS cochlear otosclerosis     │
         └──────────────┬───────────────────────┘
                        ▼
           Assess degree of hearing loss
                        │
          ┌─────────────┴─────────────┐
          ▼                           ▼
   MILD–MODERATE SNHL           SEVERE–PROFOUND SNHL
   (PTA < 70 dB)                (PTA > 70 dB, SDS < 50%)
          │                           │
          ▼                           ▼
  MEDICAL MANAGEMENT         COCHLEAR IMPLANT
  + Hearing Aid               EVALUATION
  (Sodium Fluoride,
   Bisphosphonates)

---

DIFFERENTIAL DIAGNOSIS

---

MANAGEMENT

A. MEDICAL MANAGEMENT

1. Sodium Fluoride Therapy

SODIUM FLUORIDE
       │
       ↓
Converts Hydroxyapatite → FLUORAPATITE
(in otic capsule bone)
       │
       ↓
More resistant to enzymatic resorption
       │
       ↓
Inhibits osteoclast activity
       │
       ↓
Stabilizes / arrests otosclerotic progression
       │
       ↓
Prevents further SNHL deterioration

• Dose: Sodium fluoride 40–60 mg/day (Shambaugh regimen)
• Active phase (Schwartze sign positive): Higher dose
• Duration: Long-term (years); reduce dose once Schwartze sign disappears
• (Shambaugh & Scott-Brown's regimen)

• Halts progression of cochlear SNHL in active phase
• (Shambaugh GE Jr. — pioneered fluoride therapy for cochlear otosclerosis)
• (Harrison's, p. 1024: "Fluoride therapy to prevent hearing loss from cochlear otosclerosis")
• Reduces activity on HRCT (halo diminishes)

• GI irritation (take with meals)
• Skeletal fluorosis (with excessive long-term use)
• Mottling of teeth (if in children)
• Contraindicated in renal failure, pregnancy

• Repeat PTA every 6 months
• HRCT at 1–2 years to assess radiological response

2. Bisphosphonates

• Etidronate, Pamidronate, Zoledronic acid
• Inhibit osteoclast-mediated bone resorption
• Emerging evidence as alternative/adjunct to fluoride
• (Recent advances — Quesnel et al., 2012; Mega et al.)

3. Calcium + Vitamin D

• Supplemented alongside fluoride therapy
• Prevents secondary hypo-mineralization
• Dose: Calcium 400 mg + Vitamin D 400 IU/day with fluoride

4. Bisphosphonate + Fluoride Combination

• Synergistic effect theorized
• Limited clinical evidence; under investigation

5. Role of Estrogen Modulation

• Avoid oral contraceptive pills (accelerate disease)
• SERMs (selective estrogen receptor modulators) under research

6. Anti-viral Agents (Experimental)

• Measles vaccination — population-level prevention
• Anti-measles immunization has reduced new-onset otosclerosis incidence in vaccinated cohorts

B. SURGICAL MANAGEMENT

1. Stapedectomy / Stapedotomy

• Indication: Conductive or mixed hearing loss with significant air-bone gap (>25 dB)
• Effect on cochlear SNHL: Does NOT improve the sensorineural component
• Restores conductive component; cochlear SNHL persists
• Risk: Floating footplate, dead ear (1–2%), perilymph gusher

SURGICAL OPTIONS:
├─ Total Stapedectomy (Shea's original — removed entire footplate)
├─ Partial Stapedectomy
└─ Stapedotomy (preferred — small fenestra 0.6–0.8mm, less cochlear trauma)
    │
    └─ Prosthesis options:
       ├─ Teflon piston
       ├─ Titanium piston
       └─ Nitinol (shape memory alloy) — recent advance

2. Hearing Aids

• Indicated for: Cochlear SNHL when surgery cannot help
• Types: BTE, ITE, ITC, CIC — digital hearing aids preferred
• Effective for mild–moderate SNHL
• BAHA (Bone-Anchored Hearing Aid): Option for mixed HL when surgery contraindicated

3. Cochlear Implantation (CI) — Most Important in Pure Cochlear Otosclerosis

• Bilateral severe-to-profound SNHL (PTA > 70 dB in better ear)
• Word Recognition Score (WRS) < 50% with optimal hearing aid
• No benefit from conventional hearing aids
• Absence of active cochlear disease (relative — can implant after fluoride stabilization)

CHALLENGES FOR CI IN COCHLEAR OTOSCLEROSIS:
                    │
    ┌───────────────┼───────────────┐
    ▼               ▼               ▼
PARTIAL/COMPLETE  INCREASED       ELECTRODE
COCHLEAR          FIBROSIS &      MISPLACEMENT
OBLITERATION      OSSIFICATION    RISK
    │               │               │
    ▼               ▼               ▼
Drill through   Reduced            Shortened
ossified        impedance          electrode arrays
cochlea         predictability
    │
    ▼
Risk of FACIAL NERVE INJURY
(aberrant course due to bone remodeling)

• Cochleostomy / Extended Round Window approach
• Drill-out procedure for obliterated cochlea
• Split-electrode array for severely obliterated cochleae
• Intraoperative Neural Response Telemetry (NRT) / ECAP monitoring

• Generally good speech perception outcomes even with partial insertion
• Better outcomes if implanted before complete cochlear ossification
• Results comparable to other etiologies with early implantation
• (Papsin BC, Cummings Otolaryngology; Hazarika ENT)

PRE-COCHLEAR IMPLANT WORKUP IN COCHLEAR OTOSCLEROSIS:
    │
    ├─ HRCT Temporal Bone → cochlear patency, Rotteveel grade
    ├─ MRI (Gd) → cochlear nerve status, endolymph
    ├─ ABR → cochlear nerve function
    ├─ Vestibular assessment (ENG/VNG)
    ├─ Ophthalmology (Usher syndrome exclusion)
    └─ Fluoride course (6 months pre-op to reduce active disease)

---

FLOWCHART: MANAGEMENT ALGORITHM

COCHLEAR OTOSCLEROSIS CONFIRMED
              │
              ▼
    ASSESS SCHWARTZE SIGN
    + CT ACTIVITY (Halo present?)
              │
    ┌─────────┴──────────┐
    ▼                    ▼
  ACTIVE              INACTIVE
(Halo present,      (Dense, no halo)
 Schwartze +ve)
    │                    │
    ▼                    ▼
SODIUM FLUORIDE    HEARING AID TRIAL
40–60 mg/day +       (3–6 months)
Ca + Vit D               │
    │              ┌──────┴───────┐
    ▼              ▼              ▼
Monitor PTA     ADEQUATE      INADEQUATE
every 6/12      BENEFIT       BENEFIT
    │                          │
    ▼                          ▼
If progresses →        DEGREE OF HL
    │              ┌────────────┴─────────────┐
    ▼              ▼                          ▼
HEARING AID   MODERATE HL               SEVERE-PROFOUND
(Mild-Mod)    PTA 40–70 dB              PTA > 70 dB
              SDS > 50%                 SDS < 50%
                  │                          │
                  ▼                          ▼
          DIGITAL HEARING AID        COCHLEAR IMPLANT
          (BTE/ITC/CIC)              EVALUATION
                  │                          │
          If mixed: add                 Rotteveel Grade?
          stapedectomy for                   │
          conductive component    ┌──────────┴──────────┐
                                  ▼                     ▼
                              GRADE 1–2             GRADE 3–4
                           (Patent cochlea)     (Obliterated)
                                  │                     │
                                  ▼                     ▼
                           STANDARD CI            DRILL-OUT + CI
                           ELECTRODE             (Modified approach)

---

COMPLICATIONS AND PROGNOSIS

• Sodium fluoride arrests progression in 70–80% of active cases
• Stapedectomy: >90% excellent closure of ABG for fenestral component
• CI outcomes: 60–80% open-set speech discrimination at 1 year
• Poor prognostic factors: older age, longer duration of deafness, obliterative cochlear otosclerosis

---

VAN DER HOEVE SYNDROME

---

RECENT ADVANCES (Crucial for RGUHS 50-Marks Answer)

1. Gene Therapy

• OTSC gene loci sequencing enabling identification of at-risk families
• COL1A1, TGFB1, BMP2/4 pathways as therapeutic targets
• Experimental gene silencing of osteoclast activators (preclinical stage)

2. Anti-RANKL Therapy (Denosumab)

• Denosumab (anti-RANKL monoclonal antibody) inhibits osteoclastogenesis
• Case reports showing arrest of otosclerosis progression
• (Plouin-Gaudon et al., 2020 — emerging evidence)

3. Bisphosphonate Clinical Trials

• Zoledronic acid (IV annual) showing promise in preventing SNHL progression
• Reduces CT pericochlear halo activity
• (Quesnel et al., Laryngoscope, 2012)

4. Slim/Lateral Wall Electrode Arrays for Obliterated Cochleae

• Nucleus Slim Straight (CI422), Med-El FLEX arrays
• Allow full/partial insertion even in partially ossified cochleae
• (Papsin & Roland, CI outcomes in otosclerosis)

5. Intraoperative CT / Image-Guided CI

• Real-time imaging to assess electrode placement in distorted anatomy

6. Ototopical Drug Delivery

• Intratympanic/intracochlear sodium fluoride and bisphosphonate delivery systems under development
• Targeted cochlear delivery to reduce systemic side effects

7. Stem Cell Research

• Cochlear supporting cell regeneration post-hair cell loss
• Theoretical application in cochlear otosclerosis with hair cell loss

8. Machine Learning in Diagnosis

• AI-based HRCT analysis for automatic detection and grading of pericochlear halo
• Improving sensitivity of early-stage cochlear otosclerosis detection

9. Minimally Invasive Stapedotomy

• Laser stapedotomy (KTP, CO₂ diode): reduced footplate trauma, less cochlear insult
• Better preservation of residual SNHL

10. Measles Immunization Impact

• Long-term epidemiological data showing declining incidence of otosclerosis in vaccinated populations
• (Arnold W, Friedmann I, 1993 — supporting measles hypothesis)

---

SUMMARY TABLE

---

REFERENCES (Standard Textbooks)

1. Scott-Brown's Otorhinolaryngology, Head & Neck Surgery, 8th Ed. — Gleeson M et al. — Chapter on Otosclerosis
2. Cummings Otolaryngology Head & Neck Surgery, 7th Ed. — Flint PW et al. — Otosclerosis and Stapedectomy
3. Stell & Maran's Textbook of Head & Neck Surgery and Oncology, 5th Ed. — Chapter on Deafness and Otosclerosis
4. Zakir Hussain's Textbook of Clinical Otology — Cochlear Otosclerosis
5. Dhingra's Diseases of Ear, Nose & Throat, 7th Ed. — Chapter 16: Otosclerosis
6. Hazarika P. Textbook of Ear, Nose & Throat Diseases — Otosclerosis with cochlear involvement
7. Harrison's Principles of Internal Medicine, 21st Ed. (p. 1024) — Otosclerosis and cochlear extension
8. Linthicum FH Jr. & Fayad JN — Otosclerosis: Histopathologic dating and temporal bone studies
9. Shambaugh GE Jr. — Fluoride therapy for cochlear otosclerosis — Arch Otolaryngol. 1967
10. Quesnel AM et al. — Bisphosphonates for cochlear otosclerosis — Laryngoscope. 2012
11. Valvassori GE — Cochlear otosclerosis: tomographic diagnosis — Trans Am Acad Ophthalmol Otolaryngol. 1965
12. Arnold W, Friedmann I — Otosclerosis: an inflammatory disease of the otic capsule — J Laryngol Otol. 1993

---

EXAM-TIPS FOR RGUHS 50 MARKS

1. Definition + Distinction from fenestral otosclerosis (2 marks)
2. Etiology + Genetics including OTSC loci (5 marks)
3. Pathophysiology flowchart with mechanism of SNHL (8 marks)
4. Histopathology — stages, blue mantles of Manasse (5 marks)
5. Clinical features — symptom-sign table (5 marks)
6. Audiological evaluation — PTA, tympanogram, OAE, ABR (7 marks)
7. Radiological features — HRCT double ring sign, Valvassori grading (5 marks)
8. Management — Medical (fluoride protocol) + CI algorithm with flowchart (10 marks)
9. Recent advances — at least 3–4 points (3 marks)

Key phrases examiners look for: Double ring sign, Fourth ring of Valvassori, Blue mantles of Manasse, Sodium fluoride/fluorapatite, Rotteveel grading, RANKL pathway, Carhart notch (mechanical artifact), COL1A1 gene

---